Riskpilot← Back to searchSign inGet full accessNordic Pharmacon AB
ABActiveOrg 5568503162Kanholmsvägen 51 Pharmacon AbRetail sale of pharmaceutical products · NACE 4773Est. 20112 employees
Revenue 2024
SEK 7,7M
+1% vs 2023
EBITDA margin
-0.3%
-117% vs 2023
Equity ratio
40.2%
Financial strength
Net profit 2024
SEK -16K
-113% vs 2023
| Revenue | SEK 7,7M | +1% |
| EBITDA | SEK -22K | -117% |
| Net profit | SEK -16K | -113% |
| Total assets | SEK 2,4M | +8% |
| Equity | SEK 976K | -2% |
| Employees | 2 | — |
Legal name
Nordic Pharmacon AB
Org number
5568503162
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
20 april 2011
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av ledamoten Firman tecknas i förening av ledamoten suppleanten
Company purpose
Bolaget ska bedriva apoteksverksamhet och tjänster inom läkemedelsområdet samt övriga hälsobefrämjande tjänster. Bolaget skall förvalta och äga fast och lös egendom, samt idka därmed förenlig verksamhet.
Address
Kanholmsvägen 51 Pharmacon Ab
Email
apoteket@booapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 994 | 7 305 | 6 884 | 7 577 | 7 687 |
| Staff expenses | — | — | −1 422 | −1 432 | −1 444 |
| EBITDA | 453 | 88 | −69 | 131 | −22 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 453 | 88 | −69 | 131 | −22 |
| Net financials | −96 | −26 | −32 | 4 | 6 |
| Profit before tax | 357 | 61 | −101 | 136 | −16 |
| Tax | −56 | −12 | — | −8 | −0 |
| Net profit | 301 | 49 | −101 | 127 | −16 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 308 | 2 129 | 2 161 | 2 240 | 2 427 |
| Equity | 917 | 966 | 865 | 992 | 976 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 392 | 1 163 | 1 296 | 1 248 | 1 451 |
| Total debt | 1 392 | 1 163 | 1 296 | 1 248 | 1 451 |
EBITDA margin
-0.3%
This company
15.8%
Market median
-102% vs market
20202024
Equity ratio
40.2%
This company
38.2%
Market median
+5% vs market
20202024
Return on equity
-1.7%
This company
18.4%
Market median
-109% vs market
20202024
Net profit margin
-0.2%
This company
8.1%
Market median
-102% vs market
20202024
Asset turnover
3.17×
This company
1.12×
Market median
+183% vs market
20202024
Debt / equity
1.49×
This company
0.62×
Market median
-140% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Chairman | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordic Pharmacon AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Naji Noureddine | Deputy Board Member | 0 companies |
| Barbara Gibert | Chairman | 0 companies |
| Alla Samantha Gimmerson | Board of Directors | 0 companies |